Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.

Clinical and experimental immunology - 1 Jun 2014

Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P

Abstract excerpt

Natalizumab, an anti-alpha4 integrin monoclonal antibody inhibiting the adhesion of lymphocytes to the endothelium, is a widely accepted drug treatment for relapsing-remitting multiple sclerosis (RRMS). A peripheral increase of T and B lymphocytes has already been observed as an early treatment effect. This retrospective observational study was aimed to evaluate the peripheral lymphocyte subsets during a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Immunophenotyping

Share to Leukocyte Count

Share to Leukocytes, Mononuclear

Share to Lymphocyte Subsets

Share to Multiple Sclerosis

Source

Open in PubMed Open full text

Identifiers

PMID: 24387139
DOI: 10.1111/cei.12261
PMCID: PMC4008975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.PMID 24387139Read ↗

Immune surveillance in multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.Semantic proximity Read ↗

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.Semantic proximity Read ↗

Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Semantic proximity Read ↗

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patientsSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.Semantic proximity Read ↗

Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral bloodSemantic proximity Read ↗

A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.Semantic proximity Read ↗

Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.Semantic proximity Read ↗

Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patientsSemantic proximity Read ↗

[Surface phenotypes of peripheral blood mononuclear cells in multiple sclerosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.